Human evidence through 2026
A condition-by-condition evidence watch for ibogaine and neurological conditions: separating completed human findings from registrations, promotion, and speculation.
Scope note No treatment claims. No approval implied. A structured view of what human reports can—and cannot—support.
Reading the record
This page maps the available human clinical and observational material for ibogaine in traumatic brain injury, PTSD-related cognitive symptoms, neuropathic pain, multiple sclerosis, and Parkinson’s disease through 2026. The central finding is not a treatment conclusion: direct, condition-specific human evidence is limited, heterogeneous, and not sufficient to establish efficacy.
Ibogaine is a psychoactive alkaloid most often discussed in addiction contexts; its broader historical and pharmacological background is summarized in the ibogaine reference overview. That context should not be mistaken for evidence in neurological conditions. For the wider frame used across this resource, see the main evidence orientation and the explanation of our independent information approach.
Observational reports can identify questions worth studying. They cannot, by themselves, settle whether a change was caused by ibogaine, by context, by selection effects, or by concurrent care.
Condition map
Each entry identifies the type of human material that can be distinguished from stronger comparative evidence. Absence of a listed randomized controlled trial is not proof of no effect; it is an evidence gap.
01 / TBI
Reports connected to post-injury symptoms are largely observational or uncontrolled. No established randomized clinical evidence was identified that demonstrates ibogaine treats TBI-related neurological impairment. Endpoints and follow-up are inconsistent where narrative reports appear.
02 / PTSD-linked cognition
Self-reported changes in mood, trauma symptoms, or cognition may appear in uncontrolled settings, but these outcomes are not equivalent to validated neurological recovery measures. Confounding by setting, expectancy, and co-interventions remains substantial.
03 / Pain
Condition-specific human evidence remains insufficient to establish a benefit for neuropathic pain. Case-level or open-label accounts require careful separation from controlled pain trials and from claims based on mechanism alone.
04 / MS
No adequate body of peer-reviewed randomized or robust prospective human evidence was identified to support ibogaine for multiple sclerosis outcomes. Disease activity, disability measures, imaging, and relapse outcomes require disease-specific study design.
05 / Parkinson’s
No adequate condition-specific clinical evidence was identified demonstrating benefit for Parkinson’s disease symptoms or progression. Mechanistic speculation and nonclinical findings do not replace controlled human outcome data.
Methodological note
The review scope is human research and human observational reporting available through 2026 that names ibogaine or ibogaine-containing interventions alongside the listed neurological conditions or closely defined symptom domains. Peer-reviewed publications are separated from preprints, press releases, promotional material, and trial registrations. A registered study indicates an intention or protocol, not completed evidence.
For clinical-trial context, the official ClinicalTrials.gov database is useful for checking whether a study is registered and how its planned design and endpoints were described. Registration status alone does not establish findings, and a registration without results is not counted here as an efficacy result.
Evidence is organized by design: randomized controlled trial, controlled prospective study, open-label study, retrospective cohort, case series, or individual case report. Priority is given to defined sample size, prespecified endpoints, follow-up duration, attrition reporting, comparator use, and adverse-event documentation.
Safety adjudication
Reports are reviewed for whether QTc prolongation, arrhythmia, seizure-like events, neurotoxicity concerns, hospitalization, and deaths are explicitly described, temporally linked, clinically evaluated, or left unclear. QT interval changes require clinically appropriate measurement and interpretation; the FDA’s discussion of QT-related rhythm risk illustrates why rhythm-risk reporting cannot be reduced to a vague side-effect count.
Neither a missing adverse-event table nor a report that does not mention a safety event demonstrates that no event occurred. The safety and monitoring framework used by this resource keeps those distinctions explicit.
Interpretation desk
No. The available material does not establish ibogaine as a treatment for TBI, PTSD-related cognitive symptoms, neuropathic pain, multiple sclerosis, Parkinson’s disease, or other neurological conditions. The U.S. drug development and approval process provides context for why a limited and uncontrolled evidence base does not constitute approval or demonstrated clinical effectiveness.
A registration can describe a proposed study, planned sample size, and intended endpoints, but it is not a completed result. It is therefore not interpreted as human outcome evidence until results are available in a suitable report. This separation helps prevent a future study from being mistaken for an established finding.
Small, unblinded, uncontrolled samples; retrospective recall; self-selected participants; unclear dosing or co-interventions; incomplete safety reporting; and selective publication can all distort apparent effects. The research priorities outline identifies the design features needed to reduce these uncertainties.
Use it as an evidence map, not as medical or legal advice. It is designed to make study type, endpoint quality, publication status, and uncertainty easier to see before a claim is repeated or acted upon.
Evidence, held in context
For readers evaluating ibogaine neurological-condition claims, the relevant next step is often not confidence—it is identifying what study design, outcome measure, and safety detail would be needed before confidence could be warranted.
Review safety and monitoring contextFor opioid-use-specific information, the separate resource on ibogaine and opioid addiction addresses a different evidence context and should not be used to infer neurological-condition outcomes.